DepoMed, Inc. (NASDAQ:DEPO)

CAPS Rating: 4 out of 5

A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.

Recs

0
Player Avatar TMFBiologyFool (98.28) Submitted: 2/15/2011 3:14:28 PM : Outperform Start Price: $8.90 DEPO Score: -37.76

Gralise should be able to compete with generics. ER tech should pay dividends down the road.

Featured Broker Partners


Advertisement